New diabetes drug pose short term challenge to Novo
Johnson & Johnson’s new diabetes drug Invokana could challenge Novo Nordisk’s Victoza in the short run, says an analyst. But it is a very different class of drug that the new product poses the biggest threat to.
by Stefan Singh Kailay
The recent EU approval of Johnson & Johnson’s Invokana means there is another of the so-called SGLT-2 inhibitors to contend with in Europe. The first drug of this type was Forxiga from AstraZeneca and Bristol-Myers Squibb.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo drug tops list of sales growth
For abonnenter
Analyst: Obesity competition is good for Novo
For abonnenter
Novo Nordisk presents positive Tresiba data
For abonnenter
